Search

SGN-CD33A Combined with Hypomethylating Therapy Produces High Remission Rates among Older Patients with AML

Acute myeloid leukemia (AML) is an aggressive form of blood cancer in which the majority of cases express CD33 on the surface of the leukemia cells.

Read more

The root of evil: pre-leukemic clones that survive chemotherapy are linked to a higher risk of leukemia recurrence

Acute myeloid leukemia (AML) is an aggressive form of blood cancer. Treatment with intensive chemotherapy often leads to a period of freedom from overt disease called a remission. However, recurrence of the disease is common.

Read more

The interaction of von Willebrand factor with platelet glycoprotein Ib: pathological implications and clinical manifestations

The EHA Specialized Working Group (SWG) on Thrombocytopenias and Platelet Function Disorders and the EHA-SWG on Bleeding and Thrombosis are pleased to collaborate on a recent free webinar: "The interaction of von Willebrand factor with platelet glycoprotein Ib: pathological implications and clinical…

Read more

Myelodysplastic Syndromes (MDS)

The SWG on Myelodysplastic Syndromes (MDS) focuses on the promotion and exchange of scientific and clinical evidence, ideas and projects in the field of MDS.

Read more

EHA2025 delegate services [draft]

EHA is pleased to introduce delegate services for the upcoming EHA2025 Congress—services that registered participants can use prior, during, or after the event. Special airline fare

Enjoy a discounted flight rate and join us in Milan.

Read more

EHA-EBMT 2nd European CAR T Cell Meeting

Dates:             January 30 – February 1, 2020
Location:        Sitges (Barcelona), Spain
Chairs:            H Einsele, C Chabannon

The 2nd edition of this meeting is jointly organized by the European Hematology Association (EHA) and the European Society for Blood and Marrow Transplantation (EBMT).…

Read more

Revision of the EU’s pharmaceutical legislation

Background on the reformIn April 2023, the European Commission (EC) published two proposals to revise the existing (and outdated) pharmaceutical legislation. This includes legislation on medicines for children and rare diseases.

Read more

EHA-SfPM Precision Medicine Meeting

EHA and SfPM (Society for Functional Precision Medicine) are proud to present the first joint meeting on Precision Medicine.

Read more